Clinical Trials Logo
  1. Home
  2. Pancreatic Insufficiency
  3. NCT03450772

Equivalence Study to Compare Two Strengths of Creon in China — CREON  

Pancreatic Insufficiency Clinical Trial

Official title:
Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects

Clinical Trial Summary

This will be an open-label, randomized, multicenter, cross-over study in 60 subjects with PEI delivering data of 60 subjects for Pancreatin Enteric-Coated Capsules 25000 and of 60 subjects for Pancreatin Enteric-Coated Capsules 10000. The study will be conducted in up to 10 sites in China.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03450772
Study type Interventional
Source Abbott
Contact Suntje Sander, PhD
Phone +495116750
Email suntje.sander@abbott.com
Status Recruiting
Phase Phase 3
Start date August 31, 2017
Completion date April 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03279653 - Pancreatic Exocrine Insufficiency After Bariatric Surgery N/A
Completed NCT00763412 - Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis N/A
Recruiting NCT01851694 - Beta-cell Response to Incretin Hormones in Cystic Fibrosis N/A
Completed NCT01988350 - Pancreatic Insufficiency Secondary to Tobacco Exposure N/A
Completed NCT01710644 - Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Phase 1/Phase 2
Active, not recruiting NCT01012908 - Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Phase 2/Phase 3
Completed NCT01879228 - Effect of Chronic Incretin-based Therapy in Cystic Fibrosis N/A
Completed NCT00705978 - Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis Phase 3
Completed NCT00095732 - Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Phase 2
Completed NCT00513682 - Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT05466838 - PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial N/A
Completed NCT02979340 - MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
Completed NCT00432861 - Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis Phase 3
Completed NCT00406536 - Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI Phase 2
Completed NCT01144507 - Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Completed NCT05700604 - Hypoglycemia and Glucagon Response in CF
Terminated NCT02985801 - PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer Phase 1/Phase 2
Completed NCT03551691 - Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Phase 2
Completed NCT00572975 - Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Phase 4
Completed NCT00880100 - Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Phase 3